The need to standardize the monitoring of oral anticoagulant treatments has led some countries to adopt, generally, Owren's Thrombotest. Apart from needing only one reagent and being perfectly adapted to this type of monitoring, the thrombotest has the advantage of being able to be used on capillary blood and venous blood and of not being influenced by the storage of the blood samples. Its disadvantages are that it is slow to perform, difficult to automate and that it has a therapeutic range which is narrow and close to the limits of precision of the technique. The results of the Thrombotest correlate well with those of the Quick test, the activated cephalin time and the X level measured by the amidolytic technique. Until the chromogenic assays are developed, the Owren's Thrombotest provides a better homogeneity and standardization of the results coming from different laboratories.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Thrombin generation capacity is enhanced by low antithrombin activity and depends on the activity of the related coagulation factors.
Thromb J
May 2022
Sysmex Corporation, 4-4-4 Takatsukadai, Nishi-ku, Kobe, 651-2271, Japan.
Background: Supplementation with antithrombin (AT) concentrates is now common in the treatment of congenital and acquired AT deficiency. However, there is no established consensus on the target and timing of supplementation. We aimed to elucidate the effects of AT deficiency on the balance between coagulation activation and inhibition using a thrombin generation assay as in vitro global assay.
View Article and Find Full Text PDFVitamin K Effects on Gas6 and Soluble Axl Receptors in Intensive Care Patients: An Observational Screening Study.
Nutrients
November 2021
Anaesthesia & Intensive Care, Department of Clinical Sciences, Lund University, Skane University Hospital, 22185 Lund, Sweden.
Growth arrest-specific gene 6 protein (Gas6) is avitamin K-dependent tissue bound protein. Gas6 has been shown to promote growth and therapy resistance among different types of cancer as well as thromboembolism. The aim of this prospective screening study: ClinicalTrials.
View Article and Find Full Text PDFOwren's Disease: A Rare Deficiency.
Cureus
August 2021
Internal Medicine, Holy Family Hospital, Rawalpindi, PAK.
Factor V deficiency is a rare bleeding disorder, which may be due to acquired inhibitors or biallelic mutations. Factor V deficiency due to homozygous or compound heterozygous mutation (also known as Owren's disease or parahemophilia) has an estimated prevalence of one in one million people. A 22-year-old female was admitted for evaluation of longstanding menorrhagia.
View Article and Find Full Text PDFIntravenous Vitamin K1 for the Correction of Prolonged Prothrombin Times in Non-Bleeding Critically Ill Patients: A Prospective Observational Study.
Nutrients
July 2021
Anaesthesia & Intensive Care, Department of Clinical Sciences, Lund University, Skane University Hospital, 22184 Lund, Sweden.
The aim of this study was to evaluate the effects of vitamin K1 on various vitamin K-dependent proteins in critically ill patients with prolonged Owren PT. We included critically ill non-bleeding adult patients without liver failure or anticoagulation treatment, with Owren PT > 1.2, who were prescribed intravenous vitamin K1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!